+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

South and Central America Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class, Route of Administration, and Distribution Channel

  • ID: 5359932
  • Report
  • May 2021
  • 119 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
The immunosuppressants segment by drug class is estimated to lead the market growth during the forecast period.



According to this study, the South and Central America multiple sclerosis therapeutics market is expected to reach US$ 1,514.03 million by 2027 from US$ 1,009.82 million in 2019; it is estimated to grow at a CAGR of 6.5% from 2020 to 2027. The report highlights trends prevailing in the South and Central America multiple sclerosis therapeutics market and the factors driving market along with those that act as hindrances.

The South and Central America multiple sclerosis therapeutics market, by drug class, is segmented into immunosuppressant and immunomodulators. The immunomodulators segment held the largest share of the market in 2019, whereas the immunosuppressants segment is anticipated to register the highest CAGR in the market during the forecast period.

As per the studies published by Brazilian Congress of Neurology in Brazil, in 2020, the average prevalence of the multiple sclerosis disease is 8.69/100,000 inhabitants. Therefore, the growing prevalence of multiple sclerosis drives the growth of the South and Central America multiple sclerosis therapeutics market. Due to rise in funding across Latin America, extensive research is being carried on developing novel medicines and treatments for multiple sclerosis and other ways of identifying potential causes for multiple sclerosis. Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, and Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, which is driving the growth of the market.

South and Central America is recording the growing number of COVID-19 cases. Currently, the countries in this region are rapidly increasing its clinical programs to fight against the COVID-19 outbreak. However, research on the effects of novel coronavirus on multiple sclerosis may negatively influence the growth of the South and Central America multiple sclerosis therapeutics market. For instance, a research study titled, ‘Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina’ was conducted at Centro de Esclerosis Múltiple Buenos Aires, Argentina. As the number of COVID-19 patients is increasing exponentially across the region, there is growing need for data showing the impact of the novel coronavirus on MS.

The growth of the market is attributed to some key driving factors such as increasing prevalence of multiple sclerosis and rise in funding for multiple sclerosis research. However, the high cost of the multiple sclerosis treatment may hinder the market growth.

Merck & Co., Inc., Novartis AG, Bayer AG, Sanofi, Bristol-Myers Squibb Company, Horizon Therapeutics plc, TEVA PHARMACEUTICAL INDUSTRIES LTD, Takeda Pharmaceutical Company Limited, F. HOFFMANN-LA ROCHE LTD, and Biogen are among the leading companies operating in the South and Central America multiple sclerosis therapeutics market.

The report segments in South and Central America Multiple Sclerosis Therapeutics Market as follows:

By Drug Class
  • Immunosuppressant
  • Immunomodulators
By Route of Administration
  • Injectable
  • Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
By Country
  • Brazil
  • Argentina
  • Rest of South and Central America
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
1. Introduction
1.1 Scope of the Study
1.2 The Publisher's Research Report Guidance
1.3 Market Segmentation
1.3.1 South and Central America Multiple Sclerosis Therapeutics Market - By Drug Class
1.3.2 South and Central America Multiple Sclerosis Therapeutics Market - By Route of Administration
1.3.3 South and Central America Multiple Sclerosis Therapeutics Market - By Distribution Channel
1.3.4 South and Central America Multiple Sclerosis Therapeutics Market - By Country

2. Multiple Sclerosis Therapeutics Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South and Central America Multiple Sclerosis Therapeutics- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South and Central America (SCAM) - PEST Analysis
4.3 Expert Opinions

5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market - South and Central America Analysis
6.1 South and Central America Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis

7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 -South and Central America Analysis
10.1 South and Central America: Multiple Sclerosis Therapeutics Market
10.1.1 Overview
10.1.2 South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.1.3 Brazil: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.3.1 Brazil: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.3.2 Brazil: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
10.1.3.3 Brazil: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
10.1.3.3.1 Brazil: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)
10.1.4 Argentina: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.1 Argentina: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.2 Argentina: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
10.1.4.3 Argentina: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
10.1.4.4 Argentina: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)
10.1.5 Rest of South and Central America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.1 Rest of South and Central America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.2 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
10.1.5.3 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
10.1.5.4 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)

11. Impact of COVID-19 Pandemic on South and Central America Multiple Sclerosis Therapeutics Market
11.1 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview

13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 F. HOFFMANN-LA ROCHE LTD.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Biogen
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

List of Tables
Table 1. Brazil Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 2. Brazil Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 3. Brazil Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 4. Argentina Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 5. Argentina Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 6. Argentina Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 7. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 8. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 9. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 10. Organic Developments Done By Companies
Table 11. Inorganic Developments Done By Companies
Table 12. Glossary of Terms, Multiple sclerosis therapeutics Market

List of Figures
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share of Multiple Sclerosis Therapeutics Market
Figure 5. South and Central America Multiple Sclerosis Therapeutics Market - Leading Country Markets (US$ Million)
Figure 6. South and Central America (SCAM) PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. South and Central America Multiple Sclerosis Therapeutics Market - Revenue Forecast and Analysis - 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 19. South and Central America: Multiple Sclerosis Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
Figure 20. South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 21. Brazil: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 22. Argentina: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 23. Rest of South and Central America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 24. Impact of COVID-19 Pandemic in South and Central America Market
Note: Product cover images may vary from those shown
  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
Note: Product cover images may vary from those shown
Adroll
adroll